T
20.30
-0.28 (-1.36%)
| Previous Close | 20.58 |
| Open | 20.63 |
| Volume | 2,529,862 |
| Avg. Volume (3M) | 2,208,476 |
| Market Cap | 1,828,619,520 |
| Price / Sales | 302.64 |
| Price / Book | 6.06 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Diluted EPS (TTM) | -1.08 |
| Total Debt/Equity (MRQ) | 0.38% |
| Current Ratio (MRQ) | 30.89 |
| Operating Cash Flow (TTM) | -71.66 M |
| Levered Free Cash Flow (TTM) | -44.95 M |
| Return on Assets (TTM) | -22.15% |
| Return on Equity (TTM) | -32.12% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Terns Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.3
| Analyst Consensus | 1.5 |
| Insider Activity | -3.0 |
| Price Volatility | -4.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | -0.30 |
|
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.28% |
| % Held by Institutions | 100.24% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Acorn Capital Advisors, Llc | 30 Jun 2025 | 1,971,264 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 32.00 (Mizuho, 57.64%) | Buy |
| Median | 25.00 (23.15%) | |
| Low | 15.00 (JMP Securities, -26.11%) | Buy |
| Average | 24.17 (19.06%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 16.30 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 11 Nov 2025 | 28.00 (37.93%) | Buy | 20.58 |
| 04 Nov 2025 | 27.00 (33.00%) | Buy | 17.43 | |
| BMO Capital | 04 Nov 2025 | 22.00 (8.37%) | Buy | 17.43 |
| HC Wainwright & Co. | 04 Nov 2025 | 20.00 (-1.48%) | Buy | 17.43 |
| 04 Sep 2025 | 7.44 (-63.35%) | Hold | 7.06 | |
| Mizuho | 04 Nov 2025 | 32.00 (57.64%) | Buy | 17.43 |
| Truist Securities | 04 Nov 2025 | 28.00 (37.93%) | Buy | 17.43 |
| 15 Oct 2025 | 20.00 (-1.48%) | Buy | 8.50 | |
| JMP Securities | 23 Oct 2025 | 15.00 (-26.11%) | Buy | 7.50 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| QUIGLEY JILL M. | - | 17.43 | -24,520 | -427,384 |
| Aggregate Net Quantity | -24,520 | |||
| Aggregate Net Value ($) | -427,384 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 17.43 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| QUIGLEY JILL M. | Director | 04 Nov 2025 | Automatic sell (-) | 24,520 | 17.43 | 427,384 |
| QUIGLEY JILL M. | Director | 04 Nov 2025 | Option execute | 24,520 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |